These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36177777)

  • 1. Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market.
    Okeniyi SO; Okereke M
    Pharm Pat Anal; 2022 Sep; 11(5):131-133. PubMed ID: 36177777
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIPS-plus and access to medicines in China.
    Chen J; Nie X; Yao P; Shi L
    J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ethics of intellectual property rights in an era of globalization.
    Shah AK; Warsh J; Kesselheim AS
    J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WTO TRIPS and its effect on the supply and development of medicines in China.
    Tanner JA
    Hong Kong Med J; 2006 Feb; 12(1):84-6. PubMed ID: 16495599
    [No Abstract]   [Full Text] [Related]  

  • 11. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
    Cohen JC; Illingworth P
    Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIPS and the global pharmaceutical market.
    Barton JH
    Health Aff (Millwood); 2004; 23(3):146-54. PubMed ID: 15160812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
    Hill JE
    Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 28478430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UK Commission concludes international patent laws hinder access to medicines in developing countries.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):59. PubMed ID: 14740605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.